Seaport Therapeutics, Inc.

Seaport Therapeutics is a clinical-stage therapeutics company dedicated to inventing and developing new medicines for patients suffering from depression, anxiety, and other debilitating neuropsychiatric disorders. Headquartered in Boston, Massachusetts, the company's mission is to transform the treatment landscape by identifying clinically validated mechanisms and overcoming historical limitations such as high first-pass metabolism, low bioavailability, and adverse side effects through its proprietary technology.

The core of Seaport Therapeutics' approach is its proprietary Glyph™ platform, a lymphatic-targeting prodrug technology. This platform is designed to bypass first-pass liver metabolism, thereby enhancing a drug's oral bioavailability, reducing side effects, and creating new composition-of-matter intellectual property. The company's pipeline includes GlyphAllo™ (SPT-300), an oral prodrug of allopregnanolone in a global Phase 2b trial for Major Depressive Disorder (MDD); GlyphAgo™ (SPT-320), a novel prodrug of agomelatine planned for Phase 2a/2b trials for Generalized Anxiety Disorder (GAD); and Glyph2BLSD™ (SPT-348), a non-hallucinogenic prodrug in preclinical development for depressive disorders and headache indications. Seaport also has GlyphCele, an oral prodrug of celecoxib, in development with ARPA-H funding.

Seaport Therapeutics recently completed an upsized initial public offering (IPO), with its common stock commencing trading on the Nasdaq Global Select Market under the ticker symbol "SPTX" on May 1, 2026, raising approximately $254.9 million in gross proceeds. The company is led by Founder, CEO, and Board Member Daphne Zohar, with Steven M. Paul, M.D., serving as Founder and Chair of the Board of Directors. The leadership team brings extensive experience in neuropsychiatry drug development, including key roles in the success of Karuna Therapeutics.

Latest updates

Seaport Therapeutics Upsizes IPO, Prices at Top of Range

Event summary

  • Seaport Therapeutics priced its upsized IPO of 14.16 million shares at $18.00 per share.
  • The offering is expected to generate gross proceeds of $254.9 million.
  • The underwriters have a 30-day option to purchase an additional 2.124 million shares.
  • Shares will begin trading on Nasdaq Global Select Market under the ticker SPTX on May 1, 2026.
  • The offering is expected to close on May 4, 2026, subject to customary conditions.

The big picture

Seaport’s successful upsized IPO, priced at the top of its range, indicates strong investor appetite for neuropsychiatric therapeutics, a market driven by unmet needs and increasing awareness of mental health disorders. The company’s Glyph platform, designed to overcome limitations in existing therapies, represents a differentiated approach that could command a premium. The $254.9 million raised provides significant runway for clinical development, but execution risk remains high given the inherent challenges in drug development.

What we're watching

Market Reception
The initial trading performance of SPTX will reveal investor sentiment towards neuropsychiatric drug development and Seaport’s Glyph platform, potentially influencing future biotech IPOs.
Underwriter Option
Whether or not the underwriters exercise their option to purchase additional shares will signal their confidence in the long-term prospects of Seaport Therapeutics.
Clinical Pipeline
The pace of clinical trial progress and data readouts for Seaport’s pipeline candidates will be critical in justifying the IPO valuation and maintaining investor interest.

Seaport Therapeutics Adds Intra-Cellular Therapies Founder to Board

Event summary

  • Seaport Therapeutics appointed Dr. Sharon Mates, former Co-Founder, Chairman, and CEO of Intra-Cellular Therapies, to its Board of Directors.
  • Intra-Cellular Therapies was acquired by Johnson & Johnson in 2025 for approximately $14.6 billion.
  • Dr. Mates oversaw the development and commercialization of CAPLYTA®, generating over $1.5 billion in sales prior to the acquisition.
  • Dr. Mates currently serves on the boards of Medincell and Benitec and is forming a new company focused on inflammation and metabolism.

The big picture

The addition of a seasoned executive like Dr. Mates, fresh from a $14.6 billion exit, underscores the increasing importance of specialized expertise in neuropsychiatry drug development. Seaport’s acquisition of this talent signals a desire to accelerate its pipeline and potentially pursue a similar exit strategy. The move also reflects a broader trend of biotech companies seeking experienced leadership to navigate the complexities of drug development and commercialization.

What we're watching

Governance Dynamics
Dr. Mates’ involvement signals a potential shift in Seaport’s strategic direction, and her experience will likely influence the company’s approach to future partnerships and acquisitions.
Pipeline Progression
The speed at which Seaport can leverage Dr. Mates’ expertise to accelerate its Glyph™ platform and clinical programs will be a key indicator of the board’s effectiveness.
New Venture Impact
How Dr. Mates balances her commitments to Seaport, Medincell, Benitec, and her new company will influence her bandwidth and impact on Seaport’s strategic decisions.
CID: 3109